Poll: 69 Percent of Americans Worried Fast-Tracked COVID-19 Vaccines Won’t Be Safe

Poll: 69 Percent of Americans Worried Fast-Tracked COVID-19 Vaccines Won’t Be Safe

Numerous polls have been conducted during the last few months asking Americans if they would get a COVID-19 vaccine were it approved by the U.S. government and offered to the public. Polls in April-May 2020 showed that about half or more of those surveyed said they would get the vaccine. More recent polling, however, has […]

A Grade 3 Vaccine-Related Adverse Event is Serious

A Grade 3 Vaccine-Related Adverse Event is Serious

When Moderna, Inc. announced on May 18, 2020 the results of a Phase 1 human clinical trial for its experimental mRNA-1273 vaccine for COVID-19, the biotechnology company said the vaccine had produced no “serious adverse events” (SAEs) among the 45 people who participated in the trial and that it considered the vaccine to be “generally […]

81 Percent of Clinical Trial Volunteers Suffer Reactions to CanSino Biologics’ COVID-19 Vaccine That Uses HEK293 Human Fetal Cell Lines

81 Percent of Clinical Trial Volunteers Suffer Reactions to CanSino Biologics’ COVID-19 Vaccine That Uses HEK293 Human Fetal Cell Lines

An experimental vaccine for COVID-19 is being developed by CanSino Biologics, Inc. of Tianjin, China, in partnership with China’s Academy of Military Medical Sciences’ Institute of Biotechnology. A Phase 1 human clinical trial of the COVID-19 vaccine (adenovirus type-5 Ad5-nCoV) has been completed in China involving 108 volunteers, ranging in age from 45–60 years old.1 […]

GSK and Sanofi COVID-19 Vaccine Produced in Insect Cells with Squalene Adjuvant

GSK and Sanofi COVID-19 Vaccine Produced in Insect Cells with Squalene Adjuvant

Story Highlights GlaxoSmithKline and Sanofi Pasteur are partnering to develop an experimental COVID-19 vaccine. The two global vaccine manufacturers are using existing recombinant DNA vaccine technology and a squalene adjuvant for their COVID-19 vaccine. Clinical trials are scheduled to begin in the second half of 2020 and, if successful, the vaccine will be available in […]